Astrazeneca shares rose nearly 1% following unexpectedly positive interim results from a Phase III trial of its breast cancer drug Camizestrant. The study revealed that patients with hormone ...

We recently published a list of the 10 Best Vaccine Stocks to Buy According to Hedge Funds. In this article, we are going to ...

AstraZeneca's SERENA-6 trial shows camizestrant plus a CDK4/6 inhibitor improves progression-free survival in HR-positive, HER2-negative breast cancer.

Bank of America analysts estimate a peak sales potential of $6 billion for camizestrant across the SERENA-6 and SERENA-4 ...

New York State Common Retirement Fund grew its position in AstraZeneca PLC (NASDAQ:AZN – Free Report) by 7.4% during the 4th ...

We recently compiled a list of the 20 High Growth Mega Cap Stocks You Can Buy And Hold For Next 5 Years. In this article, we ...

SOPHiA GENETICS enables institutions across the globe to launch world-class oncology testing BOSTON, MA and ROLLE, Switzerland, Feb. 24, 2025 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH) ...

However, the Vanguard S&P 500 Growth ETF isn't the best performer in the Vanguard family so far in 2025. Instead, it's an ETF ...

We recently compiled a list of the 10 Cheap Pharmaceutical Stocks to Buy According to Analysts. In this article, we are going ...

AstraZeneca PLC (NASDAQ:AZN – Get Free Report) was the target of some unusual options trading activity on Thursday. Stock traders bought 153,234 call options on the stock. This represents an increase ...

The stable outlook reflects Moody's expectation that AstraZeneca will maintain solid organic growth in revenues and EBITDA and continue to execute successfully on its new product pipeline. The outlook ...

Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against AstraZeneca PLC ("AstraZeneca" or the "Company") and reminds investors of the Feb. 21, 2025 ...